By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Research and development of innovative drug candidates for the treatment of human cancer3.18M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States10.91M100.00%